| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aminoglycosides for the treatment of gram-negative infections: therapeutic use, resistance and future outlook
|
Dworkin, Ronald J.
|
|
1999
|
21-22 |
3 |
p. 173-179
7 p.
|
artikel
|
| 2 |
Analysis of comptothecin resistance in yeast: relevance to cancer therapy
|
Benedetti, Piero
|
|
1998
|
21-22 |
3 |
p. 176-183
8 p.
|
artikel
|
| 3 |
A new resistance mechanism to cisplatin?
|
Kelland, Lloyd R.
|
|
2000
|
21-22 |
3 |
p. 139-141
3 p.
|
artikel
|
| 4 |
Anthracycline drug targeting: cytoplasmic versus nuclear – a fork in the road
|
Lothstein, Leonard
|
|
2001
|
21-22 |
3 |
p. 169-177
9 p.
|
artikel
|
| 5 |
Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance
|
Andes, David
|
|
2004
|
21-22 |
3 |
p. 185-194
10 p.
|
artikel
|
| 6 |
Bacterial resistance: A sensitive issue
|
Jansen, W.T.M.
|
|
2006
|
21-22 |
3 |
p. 123-133
11 p.
|
artikel
|
| 7 |
Book Review: AIDS Therapy
|
Mertz, Gregory J.
|
|
2000
|
21-22 |
3 |
p. 191-
1 p.
|
artikel
|
| 8 |
Calendar
|
|
|
2003
|
21-22 |
3 |
p. 163-
1 p.
|
artikel
|
| 9 |
Cancer research 2001: drug resistance, new targets and drug combinations
|
Broxterman, Henk J.
|
|
2001
|
21-22 |
3 |
p. 197-209
13 p.
|
artikel
|
| 10 |
Cancer research 2000: drug resistance, new targets and drugs in development
|
Broxterman, Henk J.
|
|
2000
|
21-22 |
3 |
p. 133-138
6 p.
|
artikel
|
| 11 |
Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
|
Jung, Laura L.
|
|
2001
|
21-22 |
3 |
p. 152-167
16 p.
|
artikel
|
| 12 |
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases
|
Acharya, Milin R.
|
|
2004
|
21-22 |
3 |
p. 195-208
14 p.
|
artikel
|
| 13 |
Chloroquine – some open questions on its antimalarial mode of action and resistance
|
Ginsburg, Hagai
|
|
1999
|
21-22 |
3 |
p. 180-187
8 p.
|
artikel
|
| 14 |
Clinical applications of telomerase in cancer treatment
|
Faraoni, Isabella
|
|
2000
|
21-22 |
3 |
p. 161-170
10 p.
|
artikel
|
| 15 |
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
|
Pfaller, M.A.
|
|
2011
|
21-22 |
3 |
p. 164-176
13 p.
|
artikel
|
| 16 |
Combining angiogenesis inhibition and radiotherapy: A double-edged sword
|
Kleibeuker, Esther A.
|
|
2012
|
21-22 |
3 |
p. 173-182
10 p.
|
artikel
|
| 17 |
Customizing chemotherapy for colon cancer: the potential of gene expression profiling
|
Mariadason, John M
|
|
2004
|
21-22 |
3 |
p. 209-218
10 p.
|
artikel
|
| 18 |
CYP450 pharmacogenetics for personalizing cancer therapy
|
van Schaik, Ron H.N.
|
|
2008
|
21-22 |
3 |
p. 77-98
22 p.
|
artikel
|
| 19 |
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
|
Lai, Stephen Y.
|
|
2010
|
21-22 |
3 |
p. 67-78
12 p.
|
artikel
|
| 20 |
Direct activation of caspases by RGD-peptides may increase drug sensitivity of tumour cells
|
Broxterman, Henk J.
|
|
1999
|
21-22 |
3 |
p. 139-141
3 p.
|
artikel
|
| 21 |
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
|
Brabec, Viktor
|
|
2006
|
21-22 |
3 |
p. 111-122
12 p.
|
artikel
|
| 22 |
Drug resistance in Giardia: clinical versus laboratory isolates
|
Upcroft, Peter
|
|
1998
|
21-22 |
3 |
p. 166-168
3 p.
|
artikel
|
| 23 |
Drug resistance in Pneumocystis carinii: an emerging problem
|
Walker, Daniel J.
|
|
1998
|
21-22 |
3 |
p. 201-204
4 p.
|
artikel
|
| 24 |
Drug resistant falciparum malaria: clinical consequences and strategies for prevention
|
Price, R.N.
|
|
2001
|
21-22 |
3 |
p. 187-196
10 p.
|
artikel
|
| 25 |
Editorial Board
|
|
|
2009
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 26 |
Editorial Board
|
|
|
2010
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 27 |
Editorial Board
|
|
|
2003
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 28 |
Editorial Board
|
|
|
2006
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 29 |
Editorial Board
|
|
|
2008
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 30 |
Editorial Board
|
|
|
2014
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 31 |
Editorial Board
|
|
|
2004
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 32 |
Editorial Board
|
|
|
2005
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 33 |
Editorial Board
|
|
|
2007
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 34 |
Editorial Board
|
|
|
2011
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 35 |
Editorial Board
|
|
|
2012
|
21-22 |
3 |
p. i-
1 p.
|
artikel
|
| 36 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review
|
Murphy, Mark
|
|
2011
|
21-22 |
3 |
p. 177-190
14 p.
|
artikel
|
| 37 |
Evolution of antibiotic resistance at non-lethal drug concentrations
|
Andersson, Dan I.
|
|
2012
|
21-22 |
3 |
p. 162-172
11 p.
|
artikel
|
| 38 |
Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: An update
|
Wachino, Jun-ichi
|
|
2012
|
21-22 |
3 |
p. 133-148
16 p.
|
artikel
|
| 39 |
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML
|
Weisberg, Ellen
|
|
2009
|
21-22 |
3 |
p. 81-89
9 p.
|
artikel
|
| 40 |
Future perspectives for the development of P-glycoprotein modulators
|
Sandor, Victor
|
|
1998
|
21-22 |
3 |
p. 190-200
11 p.
|
artikel
|
| 41 |
Glutathione and glutathione-dependent enzymes in cancer drug resistance
|
McLellan, Lesley I.
|
|
1999
|
21-22 |
3 |
p. 153-164
12 p.
|
artikel
|
| 42 |
GST function in drug and stress response
|
Tew, Kenneth D.
|
|
1999
|
21-22 |
3 |
p. 143-147
5 p.
|
artikel
|
| 43 |
HIV/AIDS treatment: lessons from the tuberculosis experience
|
Montaner, Julio S.G.
|
|
1998
|
21-22 |
3 |
p. 157-160
4 p.
|
artikel
|
| 44 |
Hsp90 as an anti-cancer target
|
Neckers, Len
|
|
1999
|
21-22 |
3 |
p. 165-172
8 p.
|
artikel
|
| 45 |
Hyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance
|
Toole, Bryan P.
|
|
2008
|
21-22 |
3 |
p. 110-121
12 p.
|
artikel
|
| 46 |
Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways
|
Rohwer, Nadine
|
|
2011
|
21-22 |
3 |
p. 191-201
11 p.
|
artikel
|
| 47 |
Implication of microRNAs in drug resistance for designing novel cancer therapy
|
Sarkar, Fazlul H.
|
|
2010
|
21-22 |
3 |
p. 57-66
10 p.
|
artikel
|
| 48 |
Influenza virus resistance to neuraminidase inhibitors
|
Mendel, Dirk B.
|
|
1998
|
21-22 |
3 |
p. 184-189
6 p.
|
artikel
|
| 49 |
Invasive Candida infections in the neonate
|
Brian Smith, P.
|
|
2005
|
21-22 |
3 |
p. 147-162
16 p.
|
artikel
|
| 50 |
In vivo veritas: Bcl-2 and Bcl-XLmediate tumor cell resistance to chemotherapy
|
Fujita, Naoya
|
|
2000
|
21-22 |
3 |
p. 149-154
6 p.
|
artikel
|
| 51 |
β -Lactamases: which ones are clinically important?
|
Rice, Louis B
|
|
2000
|
21-22 |
3 |
p. 178-189
12 p.
|
artikel
|
| 52 |
Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges
|
Sobel, Jack D.
|
|
1999
|
21-22 |
3 |
p. 148-152
5 p.
|
artikel
|
| 53 |
Liposomal formulations of anticancer drugs: selectivity and effectiveness
|
Massing, Ulrich
|
|
2000
|
21-22 |
3 |
p. 171-177
7 p.
|
artikel
|
| 54 |
Literature Highlights: Recent research in infectious disease drug resistance
|
|
|
2006
|
21-22 |
3 |
p. 174-179
6 p.
|
artikel
|
| 55 |
Literature Highlights (YDRUP 8/3) Recent research in infectious disease drug resistance
|
|
|
2005
|
21-22 |
3 |
p. 171-176
6 p.
|
artikel
|
| 56 |
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy
|
Wu, William K.K.
|
|
2010
|
21-22 |
3 |
p. 87-92
6 p.
|
artikel
|
| 57 |
Meetings Calendar
|
|
|
2009
|
21-22 |
3 |
p. 90-94
5 p.
|
artikel
|
| 58 |
Meetings calendar
|
|
|
1998
|
21-22 |
3 |
p. 219-
1 p.
|
artikel
|
| 59 |
MEETINGS CALENDAR
|
|
|
2001
|
21-22 |
3 |
p. 211-215
5 p.
|
artikel
|
| 60 |
MEETINGS CALENDAR
|
|
|
2000
|
21-22 |
3 |
p. 193-196
4 p.
|
artikel
|
| 61 |
Meetings Calendar
|
|
|
2006
|
21-22 |
3 |
p. 180-183
4 p.
|
artikel
|
| 62 |
Meetings Calendar
|
|
|
2004
|
21-22 |
3 |
p. 223-226
4 p.
|
artikel
|
| 63 |
Meetings Calendar
|
|
|
2007
|
21-22 |
3 |
p. 131-133
3 p.
|
artikel
|
| 64 |
Meetings Calendar
|
|
|
2008
|
21-22 |
3 |
p. 122-
1 p.
|
artikel
|
| 65 |
Modifications of DNA by platinum complexes
|
Brabec, Viktor
|
|
2005
|
21-22 |
3 |
p. 131-146
16 p.
|
artikel
|
| 66 |
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase
|
Alcaro, Stefano
|
|
2011
|
21-22 |
3 |
p. 141-149
9 p.
|
artikel
|
| 67 |
Multifaceted roles of cyclooxygenase-2 in lung cancer
|
Riedl, Karen
|
|
2004
|
21-22 |
3 |
p. 169-184
16 p.
|
artikel
|
| 68 |
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
|
Shapira, Alina
|
|
2011
|
21-22 |
3 |
p. 150-163
14 p.
|
artikel
|
| 69 |
New developments: Chloroquine-resistance in Plasmodium falciparum
|
Warhurst, David
|
|
2001
|
21-22 |
3 |
p. 141-144
4 p.
|
artikel
|
| 70 |
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
|
Tortora, Giampaolo
|
|
2007
|
21-22 |
3 |
p. 81-100
20 p.
|
artikel
|
| 71 |
Physiology and molecular genetics of multidrug resistance in Entamoeba histolytica
|
Orozco, Esther
|
|
1999
|
21-22 |
3 |
p. 188-197
10 p.
|
artikel
|
| 72 |
Prediction of dynamical drug sensitivity and resistance by module network rewiring-analysis based on transcriptional profiling
|
Zeng, Tao
|
|
2014
|
21-22 |
3 |
p. 64-76
13 p.
|
artikel
|
| 73 |
Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents
|
Le Tourneau, Christophe
|
|
2008
|
21-22 |
3 |
p. 99-109
11 p.
|
artikel
|
| 74 |
Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications for future therapeutic approaches
|
Schleicher, Stephen M.
|
|
2010
|
21-22 |
3 |
p. 79-86
8 p.
|
artikel
|
| 75 |
Prospects for development of vaccines against fungal diseases
|
Dan, Jennifer M.
|
|
2006
|
21-22 |
3 |
p. 105-110
6 p.
|
artikel
|
| 76 |
Recent research in infectious disease drug resistance
|
|
|
2003
|
21-22 |
3 |
p. 157-161
5 p.
|
artikel
|
| 77 |
Recent research in infectious disease drug resistance
|
|
|
2004
|
21-22 |
3 |
p. 219-222
4 p.
|
artikel
|
| 78 |
Regular Article
|
|
|
1999
|
21-22 |
3 |
p. 203-204
2 p.
|
artikel
|
| 79 |
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
|
van Ingen, Jakko
|
|
2012
|
21-22 |
3 |
p. 149-161
13 p.
|
artikel
|
| 80 |
Resistance of Helicobacter pylori to antibiotics and its impact on treatment options
|
Mégraud, Francis
|
|
2001
|
21-22 |
3 |
p. 178-186
9 p.
|
artikel
|
| 81 |
Resistance to amphotericin B: emerging clinical and microbiological patterns
|
Sterling, Timothy R.
|
|
1998
|
21-22 |
3 |
p. 161-165
5 p.
|
artikel
|
| 82 |
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences
|
Broxterman, Henk J
|
|
2003
|
21-22 |
3 |
p. 111-127
17 p.
|
artikel
|
| 83 |
Resistance to echinocandin-class antifungal drugs
|
Perlin, David S.
|
|
2007
|
21-22 |
3 |
p. 121-130
10 p.
|
artikel
|
| 84 |
Resistance to tyrosine kinase inhibitors: Calling on extra forces
|
Cools, Jan
|
|
2005
|
21-22 |
3 |
p. 119-129
11 p.
|
artikel
|
| 85 |
Rho GDP dissociation inhibitors as potential targets for anticancer treatment
|
Zhang, Baolin
|
|
2006
|
21-22 |
3 |
p. 134-141
8 p.
|
artikel
|
| 86 |
Role of Jun and Jun kinase in resistance of cancer cells to therapy
|
Vasilevskaya, Irina
|
|
2003
|
21-22 |
3 |
p. 147-156
10 p.
|
artikel
|
| 87 |
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
|
Jiang, Bing-Hua
|
|
2008
|
21-22 |
3 |
p. 63-76
14 p.
|
artikel
|
| 88 |
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
|
Rapisarda, Annamaria
|
|
2009
|
21-22 |
3 |
p. 74-80
7 p.
|
artikel
|
| 89 |
Staphylococcal resistance to streptogramins and related antibiotics
|
El Solh, Névine
|
|
1998
|
21-22 |
3 |
p. 169-175
7 p.
|
artikel
|
| 90 |
Strategies to target HER2/neu overexpression for cancer therapy
|
Chen, Jin-Shing
|
|
2003
|
21-22 |
3 |
p. 129-136
8 p.
|
artikel
|
| 91 |
Sulfonamide resistance: mechanisms and trends
|
Sköld, Ola
|
|
2000
|
21-22 |
3 |
p. 155-160
6 p.
|
artikel
|
| 92 |
Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy
|
Dent, Paul
|
|
2009
|
21-22 |
3 |
p. 65-73
9 p.
|
artikel
|
| 93 |
Targeting apoptosis as an approach for gastrointestinal cancer therapy
|
Qiao, Liang
|
|
2009
|
21-22 |
3 |
p. 55-64
10 p.
|
artikel
|
| 94 |
Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery
|
Bouzin, Caroline
|
|
2007
|
21-22 |
3 |
p. 109-120
12 p.
|
artikel
|
| 95 |
The apicoplast as an antimalarial drug target
|
Ralph, Stuart A.
|
|
2001
|
21-22 |
3 |
p. 145-151
7 p.
|
artikel
|
| 96 |
The emergence of HIV resistance and new antiretrovirals: are we winning?
|
Wainberg, Mark A
|
|
2004
|
21-22 |
3 |
p. 163-167
5 p.
|
artikel
|
| 97 |
Therapeutic potential of nitric oxide in cancer
|
Bonavida, Benjamin
|
|
2006
|
21-22 |
3 |
p. 157-173
17 p.
|
artikel
|
| 98 |
The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside
|
Seyedmousavi, Seyedmojtaba
|
|
2014
|
21-22 |
3 |
p. 37-50
14 p.
|
artikel
|
| 99 |
The role of caspases in cell death and differentiation
|
Oliver, Lisa
|
|
2005
|
21-22 |
3 |
p. 163-170
8 p.
|
artikel
|
| 100 |
The role of galectin-3 in cancer drug resistance
|
Fukumori, Tomoharu
|
|
2007
|
21-22 |
3 |
p. 101-108
8 p.
|
artikel
|
| 101 |
The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates
|
Jansen, Gerrit
|
|
1998
|
21-22 |
3 |
p. 211-218
8 p.
|
artikel
|
| 102 |
The role of mutators in the emergence of antibiotic-resistant bacteria
|
Chopra, Ian
|
|
2003
|
21-22 |
3 |
p. 137-145
9 p.
|
artikel
|
| 103 |
The role of reductive enzymes in cancer cell resistance to mitomycin C
|
Cummings, Jeffrey
|
|
2000
|
21-22 |
3 |
p. 143-148
6 p.
|
artikel
|
| 104 |
The 90th Annual Meeting of the American Association for Cancer Research (AACR) Philadelphia, USA, 10–14 April 1999
|
de Jong, Steven
|
|
1999
|
21-22 |
3 |
p. 199-202
4 p.
|
artikel
|
| 105 |
Tumor suppressor gene therapy for cancer: from the bench to the clinic
|
Meng, Raymond D.
|
|
1998
|
21-22 |
3 |
p. 205-210
6 p.
|
artikel
|
| 106 |
What should be considered in the treatment of bacterial infections by multi-drug therapies: A mathematical perspective?
|
Pimenta, Francisco
|
|
2014
|
21-22 |
3 |
p. 51-63
13 p.
|
artikel
|
| 107 |
What's new in antibiotic resistance? Focus on beta-lactamases
|
Babic, Maja
|
|
2006
|
21-22 |
3 |
p. 142-156
15 p.
|
artikel
|
Tijdschrift beschrijving